Macrophage colony stimulating factor 1 receptor (MCSF1R), osteopontin
(OPN), high-mobility group protein B1 (HMGB1), glutamate dehydrogenase
(GLDH), keratin 18 (K18), and caspase-cleaved keratin 18 (ccK18) are
considered promising mechanistic biomarkers for the diagnosis of drug-induced
liver injury. Here, we aim to elucidate the impact of the sample matrix
and handling on the quantification of these emerging protein biomarkers.
We investigated effects such as time from collection to centrifugation
during serum (± gel) or EDTA plasma preparation on two assay
platforms: immunoaffinity liquid chromatography mass spectrometric
assays and sandwich immunoassays. Furthermore, we measured GLDH activity
with an enzymatic activity assay. Matrix effects were observed particularly
for HMGB1 and MCSF1R. HMGB1 levels were higher in serum than in plasma,
whereas higher concentrations of MCSF1R were observed in plasma than
in serum. A comparison of sample collection to centrifugation time ranging from 15 to 60 min demonstrated
increasing levels of HMGB1 in serum, while MCSF1R, OPN, GLDH, and
ccK18 concentrations remained stable. Additionally, there was a poor
correlation in HMGB1 and ccK18 levels between serum and plasma. Considering
the observed matrix effects, we recommend plasma as a matrix of choice
and cross-study comparison studies to be limited to those using the
same matrix.